Key policy and programmatic factors to improve influenza vaccination rates based on the experience from four high-performing countries.

Autor:	Kassianos G; Royal College of General Practitioners, London, UK., Banerjee A; Public Health England, London, UK., Baron-Papillon F; Sanofi Pasteur, Lyon, France., Hampson AW; Federation University, Mount Helen, VIC, Australia.; Immunisation Coalition, Melbourne, Australia., McElhaney JE; Health Sciences North Research Institute, Sudbury, ON, Canada., McGeer A; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.; Sinai Health System, Toronto, ON, Canada., Rigoine de Fougerolles T; Corporate Value Associates, Paris, France., Rothholz M; American Pharmacists Association, Washington, DC, USA., Seale H; School of Public Health and Community Medicine, University of New South Wales, Sydney, NSW, Australia., Tan LJ; Immunization Action Coalition, Saint Paul, MN, USA., Thomson A; Sanofi Pasteur, Lyon, France., Vitoux O; Corporate Value Associates, Paris, France.
Jazyk:	angličtina
Zdroj:	Drugs in context [Drugs Context] 2021 Jan 05; Vol. 10. Date of Electronic Publication: 2021 Jan 05 (Print Publication: 2021).
DOI:	10.7573/dic.2020-9-5
Abstrakt:	Background: Many countries consistently fail to achieve the target influenza vaccine coverage rate (VCR) of 75% for populations at risk of complications, recommended by the World Health Organization and European Council. We aimed to identify factors for achieving a high VCR in the scope of four benchmark countries with high influenza VCRs: Australia, Canada, UK and USA. Methods: Publicly available evidence was first reviewed at a global level and then for each of the four countries. Semi-structured interviews were then conducted with stakeholders meeting predefined criteria. Descriptive cluster analyses were performed to identify key factors and pillars for establishing and maintaining high VCRs. Results: No single factor led to a high VCR, and each benchmark country used a different combination of tailored approaches to achieve a high vaccine coverage. In each country, specific triggers were important to stimulate changes that led to improved vaccine coverage. A total of 42 key factors for a successful influenza vaccination programme were identified and clustered into five pillars: (1) Health Authority accountability and strengths of the influenza programme, (2) facilitated access to vaccination, (3) healthcare professional accountability and engagement, (4) awareness of the burden and severity of disease and (5) belief in influenza vaccination benefit. Each benchmark country has implemented multiple factors from each pillar. Conclusion: A wide range of factors were identified from an evaluation of four high-performing benchmark countries, classified into five pillars, thus providing a basis for countries with lower VCRs to tailor their own particular solutions to improve their influenza VCR. Competing Interests: Disclosure and potential conflicts of interest: No author received any direct payment from Sanofi Pasteur with regard to their contributions to this manuscript but could receive expenses for conference attendance for the presentation of data from this study. AT and FBP are employees of Sanofi Pasteur. AT currently works with UNICEF but the views expressed in this article are of AT and not UNICEF. AB has participated in advisory boards (Sanofi Pasteur), educational events (Sanofi Pasteur and Seqirus), and telephone interviews (Parexel). AB is an employee of Public Health England (PHE) but the views expressed in this article are of AB and not PHE. AH is a member and former Chairperson of the Immunisation Coalition (formerly the Influenza Specialist Group), an independent Australian not-for-profit organisation receiving financial support from influenza vaccine manufacturers, including Sanofi Pasteur. GK is President of the British Global and Travel Health Association and National Immunisation Lead of the Royal College of General Practitioners and has participated in advisory boards or lectured at meetings organised by Sanofi Pasteur, MSD, Seqirus, Pfizer, AstraZeneca, European Scientific Working Group on Influenza (ESWI) and UK’s National Health Service. He chairs the RAISE Pan-European Influenza Group and is Member of the ESWI Board of Directors. Additionally, GK is a former Editor in Chief of Drugs in Context and is currently Associate Editor for Primary Care. JMcE’s institution has received on her behalf honoraria and consulting fees from Sanofi for scientific presentations/participation in advisory boards and data monitoring boards (DMBs) and related travel costs, and holds an NIH R01AG048023 grant (independent of industry) comparing high-dose versus standard-dose fluzone in older adults. Her institution has also received honoraria for her presentations and participation in advisory boards and travel costs from GSK, Merck, Pfizer, ResTORbio, and Medicago for her role as a clinical trial lead from VBI and Jansen, and consulting fees for participation in DMBs for GSK and Merck. AMcG has received grants and personal fees from Sanofi Pasteur, GlaxoSmithKline, and Seqirus, outside the submitted work. TRdeF and OV are employees of Corporate Value Associates, Paris. MR’s wife is an employee of Merck. HS has received funding for investigator-driven research and fees to present at conferences/workshops and develop resources (bio-CSL/Sequiris, GSK and Sanofi Pasteur). LJT has no conflicts of interest to disclose. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2020/10/dic.2020-9-5-COI.pdf (Copyright © 2021 Kassianos G, Banerjee A, Baron-Papillon F, Hampson AW, McElhaney JE, McGeer A, Rigoine de Fougerolles T, Rothholz M, Seale H, Tan LJ, Thomson A, Vitoux O.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu